Positioning Metabolism as a Central Player in the Diabetic Heart

키워드

참고문헌 (98)

1. "Us, diabetes and a lot of facts and stats" (2019)[URL]
2. DeFronzo RA, "Type 2 diabetes mellitus", Nat Rev Dis Primers, 1, pp.15019~ (2015)
3. Shah AD, "Type 2 diabetes and incidence of cardiovascular diseases : a cohort study in 1·9 million people", Lancet Diabetes Endocrinol, 3, pp.105~113 (2015)
4. Chong CR, "Metabolic remodeling in diabetic cardiomyopathy", Cardiovasc Res, 113, pp.422~430 (2017)
5. Kodde IF, "Metabolic and genetic regulation of cardiac energy substrate preference", Comp Biochem Physiol A Mol Integr Physiol, 146, pp.26~39 (2007)
6. Heather LC, "Metabolism, hypoxia and the diabetic heart", J Mol Cell Cardiol, 50, pp.598~605 (2011)
7. McGill JB, "Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance", J Nucl Cardiol, 18, pp.421~429 (2011)
8. Mansor LS, "Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation", J Physiol, 594, pp.307~320 (2016)
9. fluoro-4-thiapalmitate, a novel PET fatty acid tracer, "Am J Physiol Endocrinol Metab", 2016, E452~E460
10. Levelt E, "Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes", Diabetes, 65, pp.44~52 (2016)
11. Rijzewijk LJ, "Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus", J Am Coll Cardiol, 52, pp.1793~1799 (2008)
12. Jagasia D, "Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease", Circulation, 103, pp.1734~1739 (2001)
13. Desrois M, "Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart", Cardiovasc Res, 61, pp.288~296 (2004)
14. Randle PJ, "The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus", Lancet, 1, pp.785~789 (1963)
15. Thompson AL, "Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance", Diabetes, 49, pp.1761~1765 (2000)
16. Berg JM, "Biochemistry" (2002), W H Freeman
17. Yu C, "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1(IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle", J Biol Chem, 277, pp.50230~50236 (2002)
18. Szendroedi J, "Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans", Proc Natl Acad Sci U S A, 111, pp.9597~9602 (2014)
19. Samuel VT, "Lipid-induced insulin resistance : unravelling the mechanism", Lancet, 375, pp.2267~2277 (2010)
20. Pégorier JP, "Control of gene expression by fatty acids", J Nutr, 134, pp.2444S~2449S (2004)
21. Bookout AL, "Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network", Cell, 126, pp.789~799 (2006)
22. Cannon MV, "Emerging role of liver X receptors in cardiac pathophysiology and heart failure", Basic Res Cardiol, 111, pp.3~ (2016)
23. Cozzone D, "Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells", Diabetologia, 49, pp.990~999 (2006)
24. Osborne TF, "Sterol regulatory element-binding proteins(SREBPs) : key regulators of nutritional homeostasis and insulin action", J Biol Chem, 275, pp.32379~32382 (2000)
25. Foufelle F, "New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose : a role for the transcription factor sterol regulatory element binding protein-1c", Biochem J, 366, pp.377~391 (2002)
26. Varga T, "PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation", Biochim Biophys Acta, 1812, pp.1007~1022 (2011)
27. Young ME, "Adaptation and maladaptation of the heart in diabetes. Part II : potential mechanisms", Circulation, 105, pp.1861~1870 (2002)
28. Campbell FM, "A role for peroxisome proliferator-activated receptor α(PPARα)in the control of cardiac malonyl-CoA levels : reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase", J Biol Chem, 277, pp.4098~4103 (2002)
29. Finck BN, "A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy : modulation by dietary fat content", Proc Natl Acad Sci U S A, 100, pp.1226~1231 (2003)
30. Parodi-Rullán RM, "Acetylation of mitochondrial proteins in the heart : the role of SIRT3", Front Physiol, 9, pp.1094~ (2018)
31. Glozak MA, "Acetylation and deacetylation of non-histone proteins", Gene, 363, pp.15~23 (2005)
32. Kim SC, "Substrate and functional diversity of lysine acetylation revealed by a proteomics survey", Mol Cell, 23, pp.607~618 (2006)
33. Venkat S, "Studying the lysine acetylation of malate dehydrogenase", J Mol Biol, 429, pp.1396~1405 (2017)
34. Still AJ, "Quantification of mitochondrial acetylation dynamics highlights prominent sites of metabolic regulation", J Biol Chem, 288, pp.26209~26219 (2013)
35. Kelley DE, "Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes", Diabetes, 51, pp.2944~2950 (2002)
36. Alrob OA, "Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling", Cardiovasc Res, 103, pp.485~497 (2014)
37. Fan J, "Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex", Mol Cell, 53, pp.534~548 (2014)
38. Baeza J, "Site-specific reactivity of nonenzymatic lysine acetylation", ACS Chem Biol, 10, pp.122~128 (2015)
39. Jing E, "Sirtuin-3(Sirt3)regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production", Proc Natl Acad Sci U S A, 108, pp.14608~14613 (2011)
40. Pham T, "Mitochondrial inefficiencies and anoxic ATP hydrolysis capacities in diabetic rat heart", Am J Physiol Cell Physiol, 307, pp.C499~C507 (2014)
41. Kuo TH, "Defective oxidative metabolism of heart mitochondria from genetically diabetic mice", Diabetes, 32, pp.781~787 (1983)
42. Dabkowski ER, "Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes", Am J Physiol Heart Circ Physiol, 299, pp.H529~H540 (2010)
43. Duncan JG, "Mitochondrial dysfunction in diabetic cardiomyopathy", Biochim Biophys Acta, 1813, pp.1351~1359 (2011)
44. Sloan RC, "Mitochondrial permeability transition in the diabetic heart : contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury", J Mol Cell Cardiol, 52, pp.1009~1018 (2012)
45. Tsutsui H, "Oxidative stress and mitochondrial DNA damage in heart failure", Circ J, 72(Suppl A), pp.A31~A37 (2008)
46. Boudina S, "Mitochondrial energetics in the heart in obesity-related diabetes : direct evidence for increased uncoupled respiration and activation of uncoupling proteins", Diabetes, 56, pp.2457~2466 (2007)
47. Rousset S, "The biology of mitochondrial uncoupling proteins", Diabetes, 53(Suppl 1), pp.S130~S135 (2004)
48. Cole MA, "A high fat diet increases mitochondrial fatty acid oxidation and uncoupling to decrease efficiency in rat heart", Basic Res Cardiol, 106, pp.447~457 (2011)
49. Bielawska AE, "Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion", Am J Pathol, 151, pp.1257~1263 (1997)
50. Finck BN, "The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus", J Clin Invest, 109, pp.121~130 (2002)
51. Boardman N, "Increased O2 cost of basal metabolism and excitation-contraction coupling in hearts from type 2 diabetic mice", Am J Physiol Heart Circ Physiol, 296, pp.H1373~H1379 (2009)
52. Neubauer S, "Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy", Circulation, 96, pp.2190~2196 (1997)
53. Diamant M, "Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus", J Am Coll Cardiol, 42, pp.328~335 (2003)
54. Control Group, "Intensive glucose control and macrovascular outcomes in type 2 diabetes", Diabetologia, 52, pp.2288~2298 (2009)
55. Sarma S, "Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure : findings from the EVEREST trial", Eur J Heart Fail, 15, pp.194~202 (2013)
56. Rena G, "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
57. UK Prospective Diabetes Study(UKPDS)Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)", Lancet, 352, pp.854~865 (1998)
58. Evans JM, "Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes : a comparison of patients treated with sulfonylureas and metformin", Diabetologia, 49, pp.930~936 (2006)
59. Eurich DT, "Improved clinical outcomes associated with metformin in patients with diabetes and heart failure", Diabetes Care, 28, pp.2345~2351 (2005)
60. Andersson C, "Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes", Eur J Endocrinol, 163, pp.593~599 (2010)
61. Bertrand L, "AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B", Am J Physiol Heart Circ Physiol, 291, pp.H239~H250 (2006)
62. Yang J, "Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis", Endocrinology, 147, pp.2728~2736 (2006)
63. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
64. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.2099~ (2017)
65. Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply", N Engl J Med, 380, pp.1881~1882 (2019)
66. Santos-Gallego CG, "Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility", J Am Coll Cardiol, 71, pp.A674~ (2018)
67. Santos-Gallego CG, "Infusion of the ketone body β-hydroxybutyrate improves left ventricular systolic function in an animal model of heart failure with reduced ejection fraction", Circulation, 138, pp.A17367~ (2018)
68. Garcia-Ropero A, "Metabolism of the failing heart and the impact of SGLT2 inhibitors", Expert Opin Drug Metab Toxicol, 15, pp.275~285 (2019)
69. Lepore JJ, "Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction", JACC Heart Fail, 4, pp.559~566 (2016)
70. Picatoste B, "Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms", PLoS One, 8, pp.e78330~ (2013)
71. Rizzo M, "Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome : an 18-month prospective study", Cardiovasc Diabetol, 15, pp.162~ (2016)
72. Nikolaidis LA, "Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy", Circulation, 110, pp.955~961 (2004)
73. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)
74. Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes", N Engl J Med, 375, pp.1834~1844 (2016)
75. Holman RR, "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 377, pp.1228~1239 (2017)
76. Margulies KB, "Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction : a randomized clinical trial", JAMA, 316, pp.500~508 (2016)
77. Tanaka A, "Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease : lessons from recent clinical cardiovascular outcomes trials", Cardiovasc Diabetol, 17, pp.85~ (2018)
78. Eldor R, "In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion", Diabetes Care, 36(Suppl 2), pp.S162~S174 (2013)
79. Yki-Järvinen H, "Thiazolidinediones", N Engl J Med, 351, pp.1106~1118 (2004)
80. Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial", Lancet, 366, pp.1279~1289 (2005)
81. Liao HW, "Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes : a systematic review and meta-analysis", BMJ Open, 7, pp.e013927~ (2017)
82. Roumie CL, "Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus : a cohort study", Ann Intern Med, 157, pp.601~610 (2012)
83. Azoulay L, "Sulfonylureas and the risks of cardiovascular events and death : a methodological meta-regression analysis of the observational studies", Diabetes Care, 40, pp.706~714 (2017)
84. Douros A, "Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events : population based cohort study", BMJ, 362, pp.k2693~ (2018)
85. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
86. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
87. Nicholl TA, "Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart", Am J Physiol, 261, pp.H1053~H1059 (1991)
88. Le Page LM, "Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy : a combined 13C hyperpolarized magnetic resonance and echocardiography study", Diabetes, 64, pp.2735~2743 (2015)
89. Kuda O, "Sulfo-N-succinimidyl oleate(SSO)inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164 : SSO also inhibits oxidized low density lipoprotein uptake by macrophages", J Biol Chem, 288, pp.15547~15555 (2013)
90. Mansor LS, "Inhibition of sarcolemmal FAT", CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia, Cardiovasc Res, pp.2017, 113[DOI]
91. Keung W, "Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice", Diabetes, 62, pp.711~720 (2013)
92. Haynie KR, "Inhibition of carnitine palymitoyltransferase1b induces cardiac hypertrophy and mortality in mice", Diabetes Obes Metab, 16, pp.757~760 (2014)
93. Mourouzis I, "The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats", J Cardiovasc Pharmacol Ther, 19, pp.457~469 (2014)
94. Morrow DA, "Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial", Circulation, 119, pp.2032~2039 (2009)
95. Sankaralingam S, "Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function : implications for the obesity paradox", Diabetes, 64, pp.1643~1657 (2015)
96. Koentges C, "SIRT3 in cardiac physiology and disease", Front Cardiovasc Med, 3, pp.38~ (2016)
97. Pillai VB, "Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3", Nat Commun, 6, pp.6656~ (2015)
98. Pillai VB, "Honokiol, an activator of sirtuin-3(SIRT3)preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice", Oncotarget, 8, pp.34082~34098 (2017)

관련 논문AI추천